NCT07497789Not yet recruiting
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases
Targeting SMYD3-Driven Metabolic Rewiring and Oxidative Stress Adaptation in Colorectal Liver Metastases
Source: ClinicalTrials.gov · Last updated 6 Apr 2026
Brief summary (registry, in English)
This study focuses on patients with colorectal cancer undergoing surgery for the primary tumor and/or liver metastases. Tumor samples collected during surgery will be used to generate patient-derived models (primary cultures, spheroids, and organoids) to study colorectal cancer stem cells. The main objective is to investigate the role of the lysine methyltransferase SMYD3 in metabolic reprogramming and adaptation to oxidative stress that enable colorectal cancer cells to survive and grow in the liver. Previous work has shown that SMYD3 is overexpressed in colorectal cancer, promotes drug resistance, and regulates key oncogenic pathways, including c-MYC and the AMPK/mTOR axis. By identifying SMYD3-dependent pathways and pharmacologic vulnerabilities in cancer stem cells within liver metastases, this study aims to support the development of new therapeutic strategies that combine SMYD3 inhibitors with approved or experimental agents targeting tumor metabolism and oxidative stress responses
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 156 (estimated)
- First submitted
- 23 Mar 2026
- Start date
- 10 May 2026
- Primary completion date
- 10 May 2027
- Lead sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
- Diseases
- Colorectal cancer
- NCT number
- NCT07497789
What you commit to
- Study type: Observational
- Planned participants: 156
- From 10 May 2026 to the primary completion date, 10 May 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Undergoing surgical intervention for a malignancy other than those specified in the inclusion criteria.
Age
- Age \< 18 years.
Other
- Lack of signed informed consent
Who the study is looking for
- Common criteria
- Age ≥ 18 years.
- Availability of residual tumor tissue from the surgical procedure that is not required for diagnostic purposes.
- Signed written informed consent for the use of biological samples for research purposes.
- Cohort/Arm 1 (Colon-rectal tumor resection)
- \- Patients undergoing surgical resection of colorectal cancer.
- Cohort/Arm 2 (Primary tumor and liver metastases resection) - Patients undergoing surgical resection of the primary colorectal tumor and liver metastases from colorectal carcinoma.
- Cohort/Arm 3 (Liver metastases resection only)
- \- Patients undergoing surgical resection of liver metastases from colorectal carcinoma previously resected at the primary site.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.